Type 2 diabetes mellitus (T2D) is a common endocrine and metabolic disorder, and poses threats to human health worldwide. Recently, microRNAs (miRNAs) have been suggested to play important roles in the pathophysiology of T2D. In this study, we explored the role of miR-3666 in T2D. miR-3666 was significantly down-regulated in the serum of T2D patients when compared to that of healthy volunteers, and miR-3666 expression level was negatively correlated with blood glucose levels of T2D patients. Overexpression of miR-3666 inhibited cell proliferation, reduced insulin secretion, and promoted cell apoptosis of pancreatic β-cell line (INS-1 cells). On the other hand, knockdown of miR-3666 had the opposite effects in INS-1 cells. The bio-informatics analysis using TargetScan revealed that adiponectin (ADIPOQ) was a downstream target of miR-3666, and the interaction between miR-3666 and ADIPOQ was validated by luciferase reporter assay. In addition, miR-3666 negatively regulated the mRNA and protein expression of ADIPOQ. Overexpression of ADIPOQ promoted insulin secretion after glucose stimulation, promoted cell proliferation, inhibited cell apoptosis, and partially abolished the effects of miR-3666 overexpression on insulin secretion, cell proliferation, and cell apoptosis of INS-1 cells. In conclusion, our results revealed that miR-3666 inhibited pancreatic cell proliferation, reduced insulin sensitivity, and promoted apoptosis by targeting ADIPOQ.
31 May 2021 in Japanese Journal of Infectious Diseases
Our previous work have identified a novel oxazolidinones structure, biaryloxazolidinone analogues containing a hydrazone moiety, as promising antibacterial agents against Gram positive strains. Based on these active structure, we synthesized a series novel oxazolidinones here and determine their anti-Mycobacterial activities in vitro and in Mycobacterium marinum (M.marinum) infected Zebra fish. The in vitro anti-Mycobacterial assay demonstrated that all of them have potent efficacy against both H37Rv and clinical Mycobacterial isolates. Among of these active agents, (S)-N-(3-(2-fluoro-4'-(2-amino-4-thiazolyl)biphenyl-4-yl)-2-oxo-1,3-oxazolidie-5-yl methyl)acetamide (compound 7), whose in vitro MIC was 10 fold lower than linezolid, showed the strongest bactericidal effects, with ~2.2 log reduction of M.marinum load in Zebra fish at 10mg/kg. Other novel oxazolidinones, compound 9, 12, 16, and 21 showed reduction range against M.marinum at 1.1-1.8 log, which showed better efficacy than linezolid did. Our results indicate that these identified compounds could be further developed as novel anti-Mycobacterial agents.